MET and glioblastoma: Because both LRIG3 and sLRIG3 inhibit the activation and rhHGF-induced activation of the MET signaling pathway, these proteins may be useful in combination with bevacizumab treatment to work alongside conventional anti-glioblastoma therapies to improve patient survival.